Navigation Links
Essentialis Promotes Aaron Berg to Chief Executive Officer

SAN DIEGO, Dec. 7, 2011 /PRNewswire/ -- Essentialis, Inc., announced today the promotion of Aaron D. Berg from President and Chief Commercial Officer to Chief Executive Officer (CEO).  Essentialis is focused on the development of a novel medicine for the treatment of cardiovascular and metabolic disease.  Mr. Berg joined Essentialis in January, 2010 bringing proven business development and product commercialization expertise to the Company and its lead compound, DCCR, now in Phase II development for patients with very high triglycerides.  Mr. Berg was also appointed to the Essentialis Board of Directors.

"Aaron Berg has brought to Essentialis expertise and knowledge from senior positions at Schering-Plough and Kos Pharmaceuticals," said Stuart Collinson, Ph.D., Chairman of the Board.  "As we now transition from mid-stage development to the next phase in our evolution, the Board of Directors recognized Aaron's cardiovascular and metabolic disease expertise make him an ideal leader for Essentialis."

About Aaron Berg

With more than 25 years of industry experience, Mr. Berg demonstrated a consistent record of advancement from sales representative to the pharma c-suite. After beginning his pharmaceutical industry career with Bristol-Myers Squibb, Mr. Berg spent 10 years with Schering-Plough, where he worked in numerous positions of increasing responsibility throughout the commercial organization. Mr. Berg was next recruited by GlaxoSmithKline to help build its newly launched diabetes franchise and then sought an entrepreneurial path.

In 2001, he joined then early stage Kos Pharmaceuticals as a marketing director and rose to Vice President, Marketing and Sales. Kos became widely viewed as a tremendous industry success story, and was acquired by Abbott Laboratories in December, 2006 for $3.6 billion.  His commercial expertise in lipid therapy and understanding of the compound DCCR led Essentialis to tap Mr. Berg as president and now CEO.

About DCCR

DCCR, is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation. It is in development for patients with very high triglycerides. Essentialis expects to initiate Phase 3 clinical trials in 2012.  DCCR is covered by multiple issued US patents, which provide composition of matter protection until 2028.  Essentialis has evaluated DCCR in several double-blind, placebo-controlled studies which demonstrated that the drug was well tolerated and statistical significance for various endpoints was achieved in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide help support the acceptable safety of DCCR.

About Essentialis, Inc.

Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases.  For more information visit


Kristie Kuhl


Aaron Berg


SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
2. Essentialis to Submit SPA for Hypertriglyceridemia
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
5. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
6. Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer
7. Prescription-Drug Plans Use of Specialty Tiers Promotes Inequalities
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. More Dangerous Than Drunk Driving, Hope Paige Designs Promotes a THUMBAND for Safe Texting
10. American Imaging Management Promotes Affordability and Choice to Health Care Consumers
11. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
Post Your Comments:
(Date:12/1/2015)... 1, 2015  Eyeon Therapeutics has received a ... treatments based on a charged hydrophilic polymer developed ... The product has been shown to be safe ... Mark Mitchnick , MD, CEO states, "This ... additional polymers in conjunction with a therapeutic agent.  ...
(Date:12/1/2015)... 1, 2015  Athletic apparel company Tommie ... to pay $1.35 million to settle Federal Trade ... copper-infused compression clothing would relieve severe and chronic ... diseases. Tommie Copper,s proposed ... and its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... diciembre de 2015  AccuTEC Blades, una ... precisión, develó hoy un nuevo logo corporativo ... El nuevo logo destaca la experiencia de ... de productos con cuchillas donde "el borde ... --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... The Multiple System Atrophy Coalition has announced the launch of its MSA Can’t ... today to coincide with Giving Tuesday 2015, a global day of fundraising. , ... be productive, to do simple daily activities like walking to the mailbox and eating ...
(Date:12/1/2015)... ... December 01, 2015 , ... Royal River Natural Foods — a locally-owned, ... post-menopausal women who took the nutritional supplement creatine, along with resistance training for a ... not take creatine. , The report is part of the December 2015 issue of ...
(Date:12/1/2015)... ... 2015 , ... Baptist Medical Center Jacksonville has implanted the ... hospital in the region providing what is known as the world’s smallest pacemaker. ... revealed recently at a medical conference and published in The New England Journal ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... to continue the expansion of the company’s growing product line of food safety ... (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
Breaking Medicine News(10 mins):